Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients
Primary Purpose
Septic Shock
Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Albumin 20% and terlipressin
Sponsored by
About this trial
This is an interventional treatment trial for Septic Shock focused on measuring Microcirculation, Terlipressin, Human Albumin 20%
Eligibility Criteria
Inclusion Criteria:
The presence of septic shock meeting all of the following criteria less than 24 hours:-
- Clinically possible or probable or microbiologically confirmed infection taking into account the definitions of the "International Sepsis Forum (ISF)"
- Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mm Hg.
- Serum lactate level > 2 mmol/l (18 mg/dl) despite adequate volume therapy.
Exclusion Criteria:
- Patients who failed to achieve target MAP despite adequate resuscitation with fluids and maximum dose of noreadrenaline.
- Acute coronary artery disease or underlying cardiac dysfunction [cardiac index (CI) <2.2 l/min/m 2 ].
- Severe liver disease (Child-Pugh grade C)
- Chronic renal failure.
- Known hypersensitivity to Norepinephrine, terlipressin and human albumin.
- Those having Raynaud's phenomenon, or a vasospastic diathesis and
- Other causes of shock e.g.; hemorrhagic hypovolaemia, cardiogenic shock, anaphylactic shock, neurogenic shock.
- Pregnant patients and lactation.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Group AT
Controlled
Arm Description
will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
Outcomes
Primary Outcome Measures
Mean Flow Index 6hs
Determination the degree the mean flow index (MFI) 6 hrs after administration albumin and terlipressin in patient with septic shock
Secondary Outcome Measures
Mean Flow Index 24hs
Determination the degree the mean flow index (MFI) 24 hrs after administration albumin and terlipressin in patient with septic shock.
Full Information
NCT ID
NCT05080543
First Posted
September 29, 2021
Last Updated
October 13, 2021
Sponsor
Amany Mousa Salama Muhammed
1. Study Identification
Unique Protocol Identification Number
NCT05080543
Brief Title
Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients
Official Title
Recruitment of Microcirculation Using Albumin 20% and Terlipressin in Patients With Septic Shock: a Randomized Controlled Double-blinded Study.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 2021 (Anticipated)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
October 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Amany Mousa Salama Muhammed
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to evaluate the effect of combining HSA 20% and terlipressin on the microcirculation in patients with septic shock using the following;-
Microcirculation recruitment by Cytocam-IDF.
Cardiac output by LiDCOrapid.
Measuring serum lactate level.
Detailed Description
Sepsis is one of the major medical problems and is responsible for high morbidity and mortality. Surviving Sepsis Campaign Guideline 2016 introduced 3-hours and 6-hours bundles in management of septic shock. The 2018 update of the Surviving Sepsis Campaign guidelines introduced the 'Hour-1 Bundle' which recommends treatment with intravenous fluids, measurement of serum lactate concentration as a marker of illness severity, administration of vasopressors, obtaining blood cultures and administering broad-spectrum antibiotics, all within the first hour.
The usual targets for resuscitation of patients with septic shock are the macro-circulatory parameters such as mean arterial blood pressure and heart rate; however, it is believed that restoration of microcirculatory parameters is not sufficient to avoid organ failure unless it was associated with improved microcirculatory perfusion. The loss of coherence between macro- and micro-circulatory parameters increases the need to evaluate the microcirculatory blood flow. So impaired microvascular perfusion is increasingly recognized as a major determinant of tissue hypoxia during sepsis and is a key factor in the pathogenesis of sepsis-induced organ failure.
Fluid resuscitation is recommended to be initiated immediately and completed within the first hour. Guidelines recommend at least a 30-mL/kg bolus of crystalloid fluid as the initial resuscitation. Crystalloid is the fluid of choice for initial resuscitation and subsequent intra-vascular volume replacement in patients with sepsis and septic shock.
Albumin in addition to crystalloids is suggested when patients require a substantial amount of crystalloids. Although the guidelines make no recommendation regarding which concentration of albumin should be used, 5% albumin is most commonly used in patients with hypovolemia to administer as much volume as possible.
In 2016, a study showed that in a rat model of normotensive endotoxemia, the infusion of 4% or 20% Human Serum Albumin "HSA" restored microvascular perfusion in otherwise unresuscitated animals. A more stable microvascular improvement noticed with 20% HSA.
Sepsis is also characterized by an enhanced activation of inflammatory and oxidative stress pathways, which leads to endothelial dysfunction and vascular hyporeactivity.
For its ability to counteract oxidative and nitrosative stress, albumin may represent not only a plasma expander but also an endothelium-modulating agent. In an experimental rodent model of endotoxemia, (HSA) prevented endothelial dysfunction and vascular hyporeactivity.
In patients with septic shock requiring vasopressors, a targeted mean arterial pressure "MAP" of 65 mm Hg within the first hour is recommended. Norepinephrine is the recommended first-line vasopressor in septic shock. If MAP is not maintained at 65 mm Hg or greater with norepinephrine alone or if the norepinephrine dose needs to be decreased, either vasopressin (up to 0.03 unit/minute) or epinephrine can be added to norepinephrine. Although norepinephrine is widely regarded as the first-line vasoactive medication in sepsis, literature continues to debate whether the early addition of vasopressin should be common practice.
Terlipressin is a synthetic analogue of vasopressin which has greater selectivity for the V1 receptor that cause vascular smooth muscle vasoconstriction in response to vasopressin and thus could be associated with fewer side effects than vasopressin.
In 2016 a study showed that terlipressin therapy was associated with good improvement in hemodynamic variables and kidney functions more than adrenaline in patients with refractory septic shock despite adequate fluid resuscitation and the use of norepinephrine.
No data was found on effect of combination of albumin and terlipressin on microcirculation in septic patients.
This study aims to investigate the effect of this combination on microcirculation using Cytocam-IDF (incident dark-field illumination), Braedius.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
Keywords
Microcirculation, Terlipressin, Human Albumin 20%
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
a randomized controlled and double-blinded
Masking
Investigator
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group AT
Arm Type
Active Comparator
Arm Description
will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
Arm Title
Controlled
Arm Type
Placebo Comparator
Arm Description
will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
Intervention Type
Drug
Intervention Name(s)
Albumin 20% and terlipressin
Other Intervention Name(s)
Microcirculation
Intervention Description
Evaluation the effect of adding 20% HSA and terlipressin on microvascular flow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
Primary Outcome Measure Information:
Title
Mean Flow Index 6hs
Description
Determination the degree the mean flow index (MFI) 6 hrs after administration albumin and terlipressin in patient with septic shock
Time Frame
6 hrs
Secondary Outcome Measure Information:
Title
Mean Flow Index 24hs
Description
Determination the degree the mean flow index (MFI) 24 hrs after administration albumin and terlipressin in patient with septic shock.
Time Frame
24 hs
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The presence of septic shock meeting all of the following criteria less than 24 hours:-
Clinically possible or probable or microbiologically confirmed infection taking into account the definitions of the "International Sepsis Forum (ISF)"
Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mm Hg.
Serum lactate level > 2 mmol/l (18 mg/dl) despite adequate volume therapy.
Exclusion Criteria:
Patients who failed to achieve target MAP despite adequate resuscitation with fluids and maximum dose of noreadrenaline.
Acute coronary artery disease or underlying cardiac dysfunction [cardiac index (CI) <2.2 l/min/m 2 ].
Severe liver disease (Child-Pugh grade C)
Chronic renal failure.
Known hypersensitivity to Norepinephrine, terlipressin and human albumin.
Those having Raynaud's phenomenon, or a vasospastic diathesis and
Other causes of shock e.g.; hemorrhagic hypovolaemia, cardiogenic shock, anaphylactic shock, neurogenic shock.
Pregnant patients and lactation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amany Mousa Salama, Assistant lecturer
Phone
+201004820018
Email
dr.amany.mousa@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Mohamed Sayed Arafa, Lecturer
Phone
+201003752053
Email
dr.3arafa1@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients
We'll reach out to this number within 24 hrs